PV Bulletin

Category

AI/GxP

Latest pharmacovigilance updates in AI/GxP.

publicFda · United States · Updated May 23, 2026

FDA posts January 2025 draft Level 1 guidance on AI use

Urgency: High

1) Inventory AI use cases that could feed regulated decisions (including PV/safety-related analyses or summaries used in regulatory interactions) and map owners/vendors. 2) For each AI use case, document context of use, intended outputs, and controls (e.g., review/approval, traceability, change management) aligned to a draft-guidance tracking plan. 3) Track the Federal Register notice and plan whether to submit comments within the window described by FDA (90 days after Federal Register publication).

Vendor OversightInspection ReadinessQPPV
SOP Impact4 SOPs
ConfidenceMedium
Relevant for: QPPV, Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: AI/GxP
Read impact briefarrow_forward
publicEma · Updated May 22, 2026

MHRA reiterates GxP data integrity spans GVP as Annex 11 evolves

Urgency: High

Ema update requires triage for Local Affiliate Compliance, Vendor Oversight, Inspection Readiness; confirm local obligations and document follow-up actions.

Local Affiliate ComplianceVendor OversightQPPV
SOP Impact7 SOPs
ConfidenceMedium
Relevant for: QPPV, Local Safety Officer, Signal Management Lead
verifiedRegulatory action: AI/GxP
Read impact briefarrow_forward

Get updates for your PV role

Subscribe to impact-first pharmacovigilance updates. Select every role you want in your digest.

Digest roles: QPPV. Work email only · workflow Vendor Oversight